HYPOLIPIDEMIC AND HYPOURICEMIC ACTION OF FENOFIBRATE IN VARIOUS TYPES OF HYPERLIPOPROTEINEMIAS
- 1 January 1980
- journal article
- research article
- Vol. 7 (1) , 73-82
Abstract
Fenofibrate, a phenoxyacid derivative of clofibrate, given at daily dose of 300 mg during 1 yr following a single blind design, significantly lowered serum triglycerides and total cholesterol in patients with various types of hyperlipoproteinemias (IIa, IV, V), and unresponsive to previous clofibrate therapy. Fenofibrate significantly reduced plasma uric acid. Side effects were few after prolonged treatment. Moderate and transient increases in creatinine phosphokinase and glutamopyruvic transaminase values were shown in some patients. An interaction with oral anticoagulants was observed.This publication has 5 references indexed in Scilit:
- Long-term effect of the combination of calcium clofibrate and calcium carbonate on serum total cholesterol, triglyceride and high density lipoprotein-cholesterol concentrations in hyperlipoproteinaemiaAtherosclerosis, 1979
- TREATMENT OF HYPERLIPOPROTEINEMIA (HLP) TYPE-II-A WITH A NEW PHENOXY-ISOBUTURIC ACID-DERIVATIVE, PROCETOFEN1979
- Plasma protein concentrations in hypertriglyceridaemic subjects. Effect of clofibrate and comparison with normal subjectsClinica Chimica Acta; International Journal of Clinical Chemistry, 1978
- CLINICAL PHARMACOKINETIC STUDY OF PROCETOFENE, A NEW HYPOLIPIDEMIC DRUG, IN VOLUNTEERS1978
- PHARMACOKINETIC STUDY AND BIOAVAILABILITY OF 3 MARKETED COMPOUNDS RELEASING P-CHLOROPHENOXYISOBUTYRIC ACID (CPIB) IN VOLUNTEERS1976